-
Frontiers in Immunology 2020is a relatively new genus of bacteria isolated primarily from medical clinical samples, although at a low rate compared to other genus members of the phylum, which are... (Review)
Review
is a relatively new genus of bacteria isolated primarily from medical clinical samples, although at a low rate compared to other genus members of the phylum, which are highly relevant in dysbiosis and disease. According to the taxonomy database at The National Center for Biotechnology Information, the genus consists of 13 species: , and and , and the subspecies subspecies vulgaris (vs. subsp.) are the newest strains featured outside that list. Although typically isolated from the human gut microbiome various species of this genus have been isolated from patients suffering from appendicitis, and abdominal and rectal abscess. It is possible that as spp. emerge, their identification in clinical samples may be underrepresented as novel MS-TOF methods may not be fully capable to discriminate distinct species as separate since it will require the upgrading of MS-TOF identification databases. In terms of pathogenicity, there is contrasting evidence indicating that may have protective effects against some diseases, including liver fibrosis, colitis, cancer immunotherapy, and cardiovascular disease. In contrast, other studies indicate is pathogenic in colorectal cancer and is associated with mental signs of depression. Gut dysbiosis seems to play a role in determining the compositional abundance of in the feces (., in non-alcoholic steatohepatitis, hepatic encephalopathy, and liver fibrosis). Since is a relatively recent sub-branch genus of the phylum, and since are commonly associated with chronic intestinal inflammation, this narrative review illustrates emerging immunological and mechanistic implications by which spp. correlate with human health.
Topics: Animals; Bacteroidetes; Dysbiosis; Gastrointestinal Microbiome; Host-Pathogen Interactions; Humans; Inflammation; Intestines; Mental Disorders; Mental Health; Neoplasms
PubMed: 32582143
DOI: 10.3389/fimmu.2020.00906 -
Journal of Thoracic Oncology : Official... Aug 2019Gut microbiome affecting the responses to immune checkpoint inhibitors against advanced NSCLC has been investigated in the Western population. However, considering...
INTRODUCTION
Gut microbiome affecting the responses to immune checkpoint inhibitors against advanced NSCLC has been investigated in the Western population. However, considering pre-existing genetic and gut microbiota variation, the relevance remains unknown in the East-Asian NSCLC population. This study is designed to explore the relationship between gut microbiome and clinical outcomes in Chinese patients with NSCLC who have received treatment using an anti-programmed death 1 (PD-1) blockade.
METHODS
Thirty-seven patients with advanced NSCLC receiving treatment with nivolumab were enrolled in CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491). Fecal samples were collected at the starting point, when patients received nivolumab, at clinical evaluation, and when disease progression was noted. 16S ribosome RNA gene sequencing was applied to assess gut microbiota profiles. Peripheral immune signatures were determined by multicolor flow cytometry in parallel.
RESULTS
When subgrouping patients into responder (R) and nonresponder according to the clinical response assessed using Response Evaluation Criteria in Solid Tumor version 1.1, R patients harbored higher diversity of gut microbiome at the starting point with stable composition during the treatment. Patients with high microbiome diversity had significantly prolonged progression-free survival when compared to those with low diversity. Compositional difference was observed between the two groups as well with the enrichment of Alistipes putredinis, Bifidobacterium longum, and Prevotella copri in R whereas Ruminococcus_unclassified enriched in nonresponding patients. Analysis of systemic immune responses using multicolor flow cytometry revealed that patients with a high abundance of microbiome diversity in the gut had a greater frequency of unique memory CD8 T cell and natural killer cell subsets in the periphery in response to anti-PD-1 therapy.
CONCLUSIONS
Our results reveal strong correlation between gut microbiome diversity and the responses to anti-PD-1 immunotherapy in Chinese patients with advanced NSCLC. Patients with favorable gut microbiome (such as those with high diversity) exhibit enhanced memory T cell and natural killer cell signatures in the periphery. These findings provide important implications for the prediction and the evaluation of anti-PD-1 immunotherapy against NSCLC in the Chinese population.
Topics: Antineoplastic Agents, Immunological; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Feces; Female; Gastrointestinal Microbiome; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor
PubMed: 31026576
DOI: 10.1016/j.jtho.2019.04.007